^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Ocular Melanoma

Related cancers:
3d
Pro-Tumorigenic Signaling Between Small Extracellular Vesicles of Cancer Cells and Bone Marrow-Derived Mesenchymal Stem Cells-An In Vitro Study. (PubMed, Int J Mol Sci)
Both the BM-MSCs and tumor cells exhibited altered secretory profiles after sEV treatment. The in vitro findings provide cumulative evidence that sEV-mediated interactions contribute to a tumor-supportive milieu or premetastatic niche at the BM in Rb.
Preclinical • Journal
|
RB1 (RB Transcriptional Corepressor 1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
6d
Congenital Corneal Staphyloma in an Asian Infant With Kabuki Syndrome Confirmed by a KMT2D Mutation. (PubMed, J Craniofac Surg)
Genetic testing identified a KMT2D gene mutation, confirming a diagnosis of Kabuki syndrome. Her left eye is developing normally with no structural abnormalities.
Journal
|
KMT2D (Lysine Methyltransferase 2D)
12d
Enrollment open
|
RB1 (RB Transcriptional Corepressor 1)
13d
MicroRNA deregulation as a method for assessing the effectiveness of brachytherapy for choroidal melanoma (PubMed, Vestn Oftalmol)
Analysis of microRNA expression levels in the blood plasma of CM patients can be used to assess the effectiveness of brachytherapy and to monitor patients within the framework of lifelong follow-up.
Journal
|
MIR155 (MicroRNA 155) • MIR223 (MicroRNA 223) • MIR27B (MicroRNA 27b)
13d
Choroidal Tumors (PubMed, Klin Monbl Augenheilkd)
Photodynamic therapy is currently considered the preferred treatment in symptomatic cases.Choroidal metastases represent the most prevalent intraocular malignancies, with a primary origin in breast or lung carcinoma. Multimodal imaging is essential for diagnosis and monitoring, and management requires interdisciplinary coordination.A structured multimodal diagnostic approach is crucial for accurate classification, risk assessment, and individualized therapeutic planning in patients with choroidal tumors.
Journal
|
BAP1 (BRCA1 Associated Protein 1)
14d
IDE196-009: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma (clinicaltrials.gov)
P2, N=160, Active, not recruiting, IDEAYA Biosciences | Recruiting --> Active, not recruiting
Enrollment closed
|
darovasertib (IDE196)
14d
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (clinicaltrials.gov)
P2, N=210, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
sunitinib
19d
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=25, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Nov 2026 --> Nov 2027 | Trial completion date: Nov 2027 --> Nov 2028
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS mutation • ER positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative
|
Opdivo (nivolumab) • Hiltonol (poly-ICLC) • PNV21 vaccine
19d
Analysis of clinical, pathological and molecular genetic characteristics of conjunctival melanoma (PubMed, Zhonghua Yan Ke Za Zhi)
Seven patients had a significant reduction of the residual mass and no tumor progression, and 3 patients did not respond to the treatment and died from the disease progression. CoM mostly occurs in the unilateral eye of middle-aged and elderly patients, more common at the bulbar conjunctiva and fornix conjunctiva, and histopathological epithelial cell types are the main types, with a high recurrence and metastasis rate.
Journal
|
MAGEA4 (Melanoma antigen family A, 4)
|
BRAF V600E • BRAF V600
20d
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver (clinicaltrials.gov)
P=N/A, N=10, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
Enrollment open
|
melphalan
23d
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC). (PubMed, J Immunother Cancer)
The vaccine was safe, well-tolerated, and immunogenic. Optimization of vaccines that include agonistic CD40 antibody is needed to enhance immunogenicity. Induction of a multifunctional CD4+ T cell response to mBRAF supports targeting shared mutated neoantigens with melanoma vaccines.
P1/2 data • Journal • IO biomarker • First-in-human
|
BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • LAMP3 (Lysosomal Associated Membrane Protein 3) • CD40 (CD40 Molecule)
|
BRAF V600E • BRAF mutation • BRAF V600
|
CDX-1140 • Hiltonol (poly-ICLC)
24d
Beyond the Globe: Molecular Diagnostics of Optic Nerve, Orbital, and Adnexal Neoplasms. (PubMed, Transl Vis Sci Technol)
These advances underscore the growing role of molecular diagnostics in improving accuracy, guiding prognostication, and refining the classification of rare ocular tumors. As high-throughput techniques continue to mature, integration with evolving spatial and single-cell-based approaches promises to expand our understanding and further personalize diagnostic and therapeutic strategies.
Journal
|
BRAF (B-raf proto-oncogene) • FGFR1 (Fibroblast growth factor receptor 1) • NF1 (Neurofibromin 1) • HMGA2 (High mobility group AT-hook 2) • NFIB (Nuclear Factor I B) • STAT6 (Signal transducer and activator of transcription 6) • PLAG1 (PLAG1 Zinc Finger) • NAB2 (NGFI-A Binding Protein 2) • PAX3 (Paired Box 3)